Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder

Soares, Cláudio N.; Thase, Michael E.; Clayton, Anita H.; Guico-Pabia, Christine J.; Focht, Kristen; Jiang, Qin; Kornstein, Susan G.; Ninan, Philip T.; Kane, Cecelia P.; Cohen, Lee S.

doi:10.1097/gme.0b013e3181d88962

Cited by 48 publications

(23 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…compared the efficacy and safety of desvenlafaxine and escitalopram in MDD with symptoms of anxiety in postmenopausal women, and the study demonstrated that there was no significant difference in their efficacy as evaluated on HAM-D17 scores. [15] Desvenlafaxine treatment achieved ≥50% response in 56-58% (HAM-D Score) and 41-48% (HAM-A Score) of patients. Our study achieved a higher response rate, 73.68% in HAM-D score and 73.7% in HAM-A score.…”

Section: Discussionmentioning

confidence: 99%

Clinical effectiveness and safety of escitalopram and desvenlafaxine in patients of depression with anxiety: A randomized, open-label controlled trial

et al. 2014

View full text Add to dashboard Cite

Aim:Selective serotonin reuptake inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRI) are effective in treating anxiety disorders associated with major depressive disorder (MDD). This randomized, controlled, parallel-group, open-label, phase 4 trial (CTRI/2012/08/002895) was undertaken to compare the effectiveness and safety of desvenlafaxine versus escitalopram, a standard antidepressant.Materials and Methods:Effectiveness was assessed using the Hamilton Depression Rating Scale (HAM-D17) and Hamilton Anxiety Rating Scale (HAM-A). Response to treatment was assessed by ≥50% decrease of baseline scores (responder rate). Safety and tolerability was evaluated by changes in routine laboratory parameters, vital signs, and adverse events reported by the subject and/or observed by the clinician.Results:Responder rates for both HAM-A and HAM-D scores at 8 weeks were better in the escitalopram group compared to the desvenlafaxine group (HAM-A 76.92% vs. 71.05%; HAM-D 79.48% vs 73.68%) but the differences were not statistically significant (P = 0.59 and P = 0.61). Within group changes of both scores, from baseline to subsequent visits in both treatment arms were statistically significant (P < 0.01).Conclusion:The effectiveness of desvenlafaxine was comparable to escitalopram, but escitalopram was better tolerated.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical effectiveness and safety of escitalopram and desvenlafaxine in patients of depression with anxiety: A randomized, open-label controlled trial

et al. 2014

View full text Add to dashboard Cite

show abstract

“…In an 8-week study that included a duloxetine reference treatment arm, adjusted mean change from baseline to final evaluation for HAM-D 17 total scores was similar in magnitude for desvenlafaxine 50 mg (-9.8) and 100 mg (-10.5; p = 0.028 vs placebo -8.7) and duloxetine 60 mg (-10.3; p = 0.047 vs placebo) [38]. Flexible dose desvenlafaxine and escitalopram did not differ significantly on the primary efficacy end point (change in HAM-D 17 total score) in the acute (8 week) or continuation phases of a 26-week study of postmenopausal women with MDD [39]. Three randomized, placebo-controlled studies have evaluated the efficacy of desvenlafaxine 50 mg/day [31,32,38].…”

Section: Clinical Efficacy and Safetymentioning

confidence: 95%

Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin–norepinephrine reuptake inhibitor

Nichols

Tourian

Tse

et al. 2010

Expert Opinion on Drug Metabolism & Toxicology

View full text Add to dashboard Cite

show abstract

“…[8] Overall, the study failed to demonstrate greater efficacy of desvenlafaxine compared to escitalopram during double-blind treatment in either phase [8] and, therefore, did not support the overall hypothesis that menopausal status (i.e. A randomized, comparator-controlled, multicentre trial evaluated the efficacy, safety and tolerability of desvenlafaxine versus escitalopram in postmenopausal outpatients with MDD.…”

Section: Introductionmentioning

confidence: 93%

Open-Label Treatment with Desvenlafaxine in Postmenopausal Women with Major Depressive Disorder Not Responding to Acute Treatment with Desvenlafaxine or Escitalopram

et al. 2011

Self Cite

View full text Add to dashboard Cite

Postmenopausal women with major depressive disorder who did not respond to acute, double-blind treatment with escitalopram or desvenlafaxine achieved modest, continued improvement with long-term, open-label desvenlafaxine therapy. Further interpretation of these findings is limited by aspects of the study design (i.e. open-label, non-placebo-controlled) and the lack of randomized comparison groups in the extension phase, which prevents statistical assessment of the efficacy of longer term treatment with desvenlafaxine. Clinicaltrials.gov identifier: NCT00406640.

show abstract

Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder

Cited by 48 publications

References 35 publications

Clinical effectiveness and safety of escitalopram and desvenlafaxine in patients of depression with anxiety: A randomized, open-label controlled trial

Clinical effectiveness and safety of escitalopram and desvenlafaxine in patients of depression with anxiety: A randomized, open-label controlled trial

Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin–norepinephrine reuptake inhibitor

Open-Label Treatment with Desvenlafaxine in Postmenopausal Women with Major Depressive Disorder Not Responding to Acute Treatment with Desvenlafaxine or Escitalopram

Contact Info

Product

Resources

About